Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,94 USD | -1,02% | -2,51% | -2,02% |
14/03 | PROQR THERAPEUTICS N.V. : Chardan Research ontvangt een koopadvies | ZM |
13/03 | ProQR Therapeutics N.V. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023 | CI |
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
RNA Based Therapeutics
100,0
%
| 4 | 100,0 % | 7 | 100,0 % | +65,99% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 4 | 100,0 % | 7 | 100,0 % | +65,99% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Daniel de Boer
CEO | Chief Executive Officer | 41 | 21-02-12 |
Founder | 60 | 21-02-12 | |
Jurriaan Dekkers
DFI | Director of Finance/CFO | - | 01-10-22 |
Sheila Sponselee
COO | Chief Operating Officer | - | 01-04-20 |
Sarah Kiely
IRC | Investor Relations Contact | - | 01-10-19 |
Andrew Morris
PRN | Corporate Officer/Principal | - | 01-01-19 |
René Beukema
LAW | General Counsel | 60 | 01-09-13 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Domenico Valerio
FOU | Founder | 67 | 21-02-12 |
Founder | 60 | 21-02-12 | |
Alison Lawton
BRD | Director/Board Member | 62 | 17-09-14 |
Bart Filius
BRD | Director/Board Member | 53 | 21-05-19 |
James Shannon
BRD | Director/Board Member | 67 | 21-06-16 |
Theresa Heggie
COO | Chief Operating Officer | 63 | 01-07-19 |
Begoña Carreño
BRD | Director/Board Member | 52 | 01-01-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 84 248 384 | 66 003 992 ( 78,34 %) | 0 | 78,34 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. |
Pharmaceuticals: Major
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,02% | 159 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,71 mld. | |
+1,69% | 22,02 mld. | |
-17,37% | 20,9 mld. | |
-9,30% | 17,85 mld. | |
-41,01% | 16,21 mld. | |
-14,85% | 15,52 mld. | |
+3,21% | 13,86 mld. | |
+33,54% | 12,04 mld. |
- Beurs
- Aandelen
- Koers PRQR
- Onderneming ProQR Therapeutics N.V.